A novel therapeutic target, GPR43; Where it stands in drug discovery

Cited 8 time in webofscience Cited 0 time in scopus
  • Hit : 84
  • Download : 0
With growing interest in human microbiome for its implication in metabolic disorders, inflammatory diseases, immune disorders and so forth, understanding the biology at the interface of the gut flora and the host becomes very important for identifying novel therapeutic avenues. GPR43 has been deorphanized and the metabolites of microbiome, such as short-chain fatty acids, serve as its natural ligands. There are numerous reports that GPR43 might be a crucial link to the novel therapies for the unmet medical needs and many drug discovery organizations are making their moves in response.
Publisher
PHARMACEUTICAL SOC KOREA
Issue Date
2012-09
Language
English
Article Type
Article
Keywords

PROTEIN-COUPLED RECEPTOR; CHAIN FATTY-ACIDS; GUT MICROBIOTA; FUNCTIONAL-CHARACTERIZATION; IDENTIFICATION; CANCER; INFLAMMATION; PROPIONATE; ACTIVATION; EXPRESSION

Citation

ARCHIVES OF PHARMACAL RESEARCH, v.35, no.9, pp.1505 - 1509

ISSN
0253-6269
DOI
10.1007/s12272-012-0900-6
URI
http://hdl.handle.net/10203/240996
Appears in Collection
MSE-Journal Papers(저널논문)
Files in This Item
There are no files associated with this item.
This item is cited by other documents in WoS
⊙ Detail Information in WoSⓡ Click to see webofscience_button
⊙ Cited 8 items in WoS Click to see citing articles in records_button

qr_code

  • mendeley

    citeulike


rss_1.0 rss_2.0 atom_1.0